Nanotheranostics: realizing the great promise?
-
Costas Pitris
Costas Pitris is currently an Associate Professor in the Department of Electrical and Computer Engineering at the University of Cyprus. Dr. Pitris completed his studies at the University of Texas at Austin (BS Honors 1993, MS 1995), Massachusetts Institute of Technology (PhD 2000), and Harvard Medical School (MD Magna Cum Laude 2002). His main research interests cover the areas of optical diagnostics and biomedical imaging. Dr. Pitris is one of the co-founders of the “KIOS Research Center for Intelligent Systems and Networks”. Dr. Pitris has published 39 peer reviewed journal publications, 119 conference proceedings, four book chapters, one book, and eight US and other patents. The citations to this work have reached more than 4400 according to the Scopus Citation Report (with a h-index of 27).
und
Andreani Odysseos
Andreani D. Odysseos, MD/PhD, is a clinical molecular oncologist actively involved in the development of advanced pre-clinical systems enabling the toxicologic and efficacy assessment of targeted nanomedicines. She has established and is currently leading the Translational Nanotherapeutics team at EPOS-Iasis, R&D and the University of Cyprus in close collaboration with local and regional clinical entities. Her major research and clinical interests involve the rational design and development of nanomedicines for personalized cancer therapy, application of “smart” nanoactuators for targeted drug delivery, unraveling the function of biological and cellular barriers in tumor management with emphasis on brain and ovarian cancer and elucidating the mechanisms underlying nano-bio-interactions in targeted nanomedicine.
Abstract
The 2nd International Conference on Nanotheranostics was successfully organized between October 29th and November 1st 2015 at Limassol, Cyprus. A nanotheranostics conference is an important initiative, expected to provide the forum for idea exchange and create a potential high-impact nanomedicine paradigm. ICoN2015 attracted the contribution of prominent entities in the nanomedicine field and has succeeded in bringing together high-caliber researchers and a promising population of young scientists at the dawn of their careers from all five continents. Major thematic areas included (i) the roadmap of nanotheranostics development in a patient-oriented approach, (ii) emerging challenges for nanotheranostic applications, (iii) nanoscience technologies for theranostic approaches, (iv) an emphasis session on cancer nanotheranostics, and (v) toxicology, regulatory issues and ethics. Recent developments and emerging challenges were elaborated by leading researchers in the field and are summarized in this report.
About the authors
Costas Pitris is currently an Associate Professor in the Department of Electrical and Computer Engineering at the University of Cyprus. Dr. Pitris completed his studies at the University of Texas at Austin (BS Honors 1993, MS 1995), Massachusetts Institute of Technology (PhD 2000), and Harvard Medical School (MD Magna Cum Laude 2002). His main research interests cover the areas of optical diagnostics and biomedical imaging. Dr. Pitris is one of the co-founders of the “KIOS Research Center for Intelligent Systems and Networks”. Dr. Pitris has published 39 peer reviewed journal publications, 119 conference proceedings, four book chapters, one book, and eight US and other patents. The citations to this work have reached more than 4400 according to the Scopus Citation Report (with a h-index of 27).
Andreani D. Odysseos, MD/PhD, is a clinical molecular oncologist actively involved in the development of advanced pre-clinical systems enabling the toxicologic and efficacy assessment of targeted nanomedicines. She has established and is currently leading the Translational Nanotherapeutics team at EPOS-Iasis, R&D and the University of Cyprus in close collaboration with local and regional clinical entities. Her major research and clinical interests involve the rational design and development of nanomedicines for personalized cancer therapy, application of “smart” nanoactuators for targeted drug delivery, unraveling the function of biological and cellular barriers in tumor management with emphasis on brain and ovarian cancer and elucidating the mechanisms underlying nano-bio-interactions in targeted nanomedicine.
Conflict of interest statement: Authors state no conflict of interest. All authors have read the journal’s Publication ethics and publication malpractice statement available at the journal’s website and hereby confirm that they comply with all its parts applicable to the present scientific work.
©2016 by De Gruyter
Artikel in diesem Heft
- Frontmatter
- In this issue
- Guest Editorial
- Nanotheranostics: is integrating therapeutics with diagnostics enough?
- What’s Up?
- What’s up in nanomedicine?
- Special section Nanotheranostics
- Review
- Intelligent drug delivery systems for the treatment of solid tumors
- Original Articles
- Ultrasound-induced doxorubicin release from folate-targeted and non-targeted P105 micelles: a modeling study
- Effect of pH, ultrasound frequency and power density on the release of calcein from stealth liposomes
- Meeting Report
- Nanotheranostics: realizing the great promise?
- Regular contributions
- Original Article
- Delivery and cytotoxicity of doxorubicin and temozolomide to primary glioblastoma cells using gold nanospheres and gold nanorods
- Opinion Paper
- How organizers of scientific meetings and journal editors could facilitate transfer of nanomedicine into the clinic
Artikel in diesem Heft
- Frontmatter
- In this issue
- Guest Editorial
- Nanotheranostics: is integrating therapeutics with diagnostics enough?
- What’s Up?
- What’s up in nanomedicine?
- Special section Nanotheranostics
- Review
- Intelligent drug delivery systems for the treatment of solid tumors
- Original Articles
- Ultrasound-induced doxorubicin release from folate-targeted and non-targeted P105 micelles: a modeling study
- Effect of pH, ultrasound frequency and power density on the release of calcein from stealth liposomes
- Meeting Report
- Nanotheranostics: realizing the great promise?
- Regular contributions
- Original Article
- Delivery and cytotoxicity of doxorubicin and temozolomide to primary glioblastoma cells using gold nanospheres and gold nanorods
- Opinion Paper
- How organizers of scientific meetings and journal editors could facilitate transfer of nanomedicine into the clinic
